FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938405616> ?p ?o ?g. }

• W2938405616 abstract "Antibody therapy of cancer is increasingly used in the clinic and has improved patient’s life expectancy. Except for immune checkpoint inhibition, the mode of action of many antibodies is to recognize overexpressed or specific tumor antigens and initiate either direct F(ab’)2-mediated tumor cell killing, or Fc-mediated effects such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity/phagocytosis (ADCC/P) after binding to activating Fc receptors. All antibodies used in the clinic are of the IgG isotype. The IgA isotype can, however, also elicit powerful anti-tumor responses through engagement of the activating Fc receptor for monomeric IgA (FcαRI). In addition to monocytes, macrophages and eosinophils as FcaRI expressing immune cells, neutrophils are especially vigorous in eliminating IgA opsonized tumor cells. However, with IgG as single agent it appears almost impossible to activate neutrophils efficiently, as we have visualized by live cell imaging of tumor cell killing. In this study, we investigated Fc receptor expression, binding and signaling to clarify why triggering of neutrophils by IgA is more efficient than by IgG. FcαRI expression on neutrophils is ~2 times and ~20 times lower than that of Fcγ receptors FcγRIIa and FcγRIIIb, but still, binding of neutrophils to IgA- or IgG-coated surfaces was similar. In addition, our data suggest that IgA-mediated binding of neutrophils is more stable compared to IgG. IgA engagement of neutrophils elicited stronger Fc receptor signaling than IgG as indicated by measuring the p-ERK signaling molecule. These observations lead us to propose that the higher stoichiometry of IgA to the FcαR/FcRγ-chain complex, activating four ITAMs (Immunoreceptor Tyrosine-based Activating Motifs) compared to a single ITAM for FcγRIIa, combined with a possible decoy role of the highly expressed FcγRIIIb, explains why IgA is much better than IgG at triggering tumor cell killing by neutrophils. We anticipate that harnessing the vast population of neutrophils by the use of IgA monoclonal antibodies can be a valuable addition to the growing arsenal of antibody-based therapeutics for cancer treatment." @default.
• W2938405616 created "2019-04-25" @default.
• W2938405616 creator A5002001213 @default.
• W2938405616 creator A5009639460 @default.
• W2938405616 creator A5015545205 @default.
• W2938405616 creator A5023430816 @default.
• W2938405616 creator A5052984671 @default.
• W2938405616 creator A5055308479 @default.
• W2938405616 creator A5056479384 @default.
• W2938405616 creator A5059670503 @default.
• W2938405616 creator A5068320500 @default.
• W2938405616 creator A5069484984 @default.
• W2938405616 date "2019-04-11" @default.
• W2938405616 modified "2023-10-18" @default.
• W2938405616 title "Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG" @default.
• W2938405616 cites W1595326503 @default.
• W2938405616 cites W1619850380 @default.
• W2938405616 cites W1878923342 @default.
• W2938405616 cites W1890466892 @default.
• W2938405616 cites W1973431219 @default.
• W2938405616 cites W1981886418 @default.
• W2938405616 cites W2012521762 @default.
• W2938405616 cites W2017098129 @default.
• W2938405616 cites W2026968254 @default.
• W2938405616 cites W2038015187 @default.
• W2938405616 cites W2043228552 @default.
• W2938405616 cites W2050233470 @default.
• W2938405616 cites W2056879158 @default.
• W2938405616 cites W2066671159 @default.
• W2938405616 cites W2069001067 @default.
• W2938405616 cites W2091943511 @default.
• W2938405616 cites W2134057839 @default.
• W2938405616 cites W2139419109 @default.
• W2938405616 cites W2143239528 @default.
• W2938405616 cites W2158608719 @default.
• W2938405616 cites W2165282675 @default.
• W2938405616 cites W2167945713 @default.
• W2938405616 cites W2183107537 @default.
• W2938405616 cites W2190773785 @default.
• W2938405616 cites W2196296332 @default.
• W2938405616 cites W2248004572 @default.
• W2938405616 cites W2280299758 @default.
• W2938405616 cites W2397170433 @default.
• W2938405616 cites W2512726762 @default.
• W2938405616 cites W2560367415 @default.
• W2938405616 cites W2576109111 @default.
• W2938405616 cites W2594014934 @default.
• W2938405616 cites W2606415265 @default.
• W2938405616 cites W2608354679 @default.
• W2938405616 cites W2614824762 @default.
• W2938405616 cites W2766522579 @default.
• W2938405616 cites W2791833398 @default.
• W2938405616 cites W2807568660 @default.
• W2938405616 cites W2811247652 @default.
• W2938405616 cites W2892250527 @default.
• W2938405616 cites W2896316027 @default.
• W2938405616 cites W2905199128 @default.
• W2938405616 cites W2911699089 @default.
• W2938405616 cites W2918786033 @default.
• W2938405616 doi "https://doi.org/10.3389/fimmu.2019.00704" @default.
• W2938405616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6470253" @default.
• W2938405616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31031746" @default.
• W2938405616 hasPublicationYear "2019" @default.
• W2938405616 type Work @default.
• W2938405616 sameAs 2938405616 @default.
• W2938405616 citedByCount "82" @default.
• W2938405616 countsByYear W29384056162019 @default.
• W2938405616 countsByYear W29384056162020 @default.
• W2938405616 countsByYear W29384056162021 @default.
• W2938405616 countsByYear W29384056162022 @default.
• W2938405616 countsByYear W29384056162023 @default.
• W2938405616 crossrefType "journal-article" @default.
• W2938405616 hasAuthorship W2938405616A5002001213 @default.
• W2938405616 hasAuthorship W2938405616A5009639460 @default.
• W2938405616 hasAuthorship W2938405616A5015545205 @default.
• W2938405616 hasAuthorship W2938405616A5023430816 @default.
• W2938405616 hasAuthorship W2938405616A5052984671 @default.
• W2938405616 hasAuthorship W2938405616A5055308479 @default.
• W2938405616 hasAuthorship W2938405616A5056479384 @default.
• W2938405616 hasAuthorship W2938405616A5059670503 @default.
• W2938405616 hasAuthorship W2938405616A5068320500 @default.
• W2938405616 hasAuthorship W2938405616A5069484984 @default.
• W2938405616 hasBestOaLocation W29384056161 @default.
• W2938405616 hasConcept C109316439 @default.
• W2938405616 hasConcept C125823703 @default.
• W2938405616 hasConcept C159654299 @default.
• W2938405616 hasConcept C170493617 @default.
• W2938405616 hasConcept C185592680 @default.
• W2938405616 hasConcept C202751555 @default.
• W2938405616 hasConcept C203014093 @default.
• W2938405616 hasConcept C2777991845 @default.
• W2938405616 hasConcept C2779931124 @default.
• W2938405616 hasConcept C2780898057 @default.
• W2938405616 hasConcept C40677261 @default.
• W2938405616 hasConcept C502942594 @default.
• W2938405616 hasConcept C542903549 @default.
• W2938405616 hasConcept C55493867 @default.
• W2938405616 hasConcept C86803240 @default.
• W2938405616 hasConcept C8891405 @default.
• W2938405616 hasConcept C89372155 @default.

• next